➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Moodys
Express Scripts
Medtronic
Mallinckrodt
McKinsey

Last Updated: April 18, 2021

36 Drugs Facing Patent Expirations and Generic Entry in 2021 - 2022

DrugPatentWatch® Estimated Loss of Exclusivity Dates

The content of this page is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

Preferred citation:
Friedman, Yali, "36 Drugs Facing Patent Expirations and Generic Entry in 2021 - 2022" DrugPatentWatch.com thinkBiotech, 2021 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
When can OPTISON (albumin human) generic drug versions launch?

Generic name: albumin human
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 20, 2021
Generic Entry Controlled by: Patent 6,723,303

OPTISON is a drug marketed by Ge Healthcare. There is one patent protecting this drug.

This drug has forty patent family members in twenty-seven countries.

See drug price trends for OPTISON.

The generic ingredient in OPTISON is albumin human. There are seven drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the albumin human profile page.

When can FIRMAGON (degarelix acetate) generic drug versions launch?

Generic name: degarelix acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 18, 2021
Generic Entry Controlled by: Patent 5,925,730

FIRMAGON is a drug marketed by Ferring. There are five patents protecting this drug.

This drug has one hundred and forty patent family members in thirty-six countries. There has been litigation on patents covering FIRMAGON

See drug price trends for FIRMAGON.

The generic ingredient in FIRMAGON is degarelix acetate. One supplier is listed for this generic product. Additional details are available on the degarelix acetate profile page.

When can CONSENSI (amlodipine besylate; celecoxib) generic drug versions launch?

Generic name: amlodipine besylate; celecoxib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 31, 2021
Generic Entry Controlled by: FDA Regulatory Exclusivity

CONSENSI is a drug marketed by Coeptis. There are three patents protecting this drug.

This drug has nine patent family members in seven countries.

The generic ingredient in CONSENSI is amlodipine besylate; celecoxib. There are fifty drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the amlodipine besylate; celecoxib profile page.

When can PERFOROMIST (formoterol fumarate) generic drug versions launch?

Generic name: formoterol fumarate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 22, 2021
Generic Entry Controlled by: Patent 8,623,922

Drug Price Trends for PERFOROMIST
PERFOROMIST is a drug marketed by Mylan Speclt. There are six patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has sixteen patent family members in nine countries. There has been litigation on patents covering PERFOROMIST

See drug price trends for PERFOROMIST.

The generic ingredient in PERFOROMIST is formoterol fumarate. There are nineteen drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the formoterol fumarate profile page.

When can NATROBA (spinosad) generic drug versions launch?

Generic name: spinosad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 02, 2021
Generic Entry Controlled by: Patent 7,030,095

Drug Price Trends for NATROBA
NATROBA is a drug marketed by Parapro Llc. There are two patents protecting this drug.

This drug has forty-eight patent family members in thirty countries.

See drug price trends for NATROBA.

The generic ingredient in NATROBA is spinosad. There is one drug master file entry for this API. Two suppliers are listed for this generic product. Additional details are available on the spinosad profile page.

When can RESCULA (unoprostone isopropyl) generic drug versions launch?

Generic name: unoprostone isopropyl
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 09, 2021
Generic Entry Controlled by: Patent 5,221,763

RESCULA is a drug marketed by Sucampo Pharma Llc. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has twenty-one patent family members in eighteen countries.

The generic ingredient in RESCULA is unoprostone isopropyl. There are four drug master file entries for this API. Additional details are available on the unoprostone isopropyl profile page.

When can SMOFLIPID 20% (fish oil; medium chain triglycerides; olive oil; soybean oil) generic drug versions launch?

Generic name: fish oil; medium chain triglycerides; olive oil; soybean oil
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 13, 2021
Generic Entry Controlled by: FDA Regulatory Exclusivity

SMOFLIPID 20% is a drug marketed by Fresenius Kabi Usa.

This drug has twenty-one patent family members in eighteen countries.

The generic ingredient in SMOFLIPID 20% is fish oil; medium chain triglycerides; olive oil; soybean oil. There are six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the fish oil; medium chain triglycerides; olive oil; soybean oil profile page.

When can INTELENCE (etravirine) generic drug versions launch?

Generic name: etravirine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 16, 2021
Generic Entry Controlled by: FDA Regulatory Exclusivity

Drug Price Trends for INTELENCE
INTELENCE is a drug marketed by Janssen R And D. There are three patents protecting this drug.

This drug has fifty-eight patent family members in thirty-five countries.

See drug price trends for INTELENCE.

The generic ingredient in INTELENCE is etravirine. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the etravirine profile page.

When can ARNUITY ELLIPTA (fluticasone furoate) generic drug versions launch?

Generic name: fluticasone furoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 03, 2021
Generic Entry Controlled by: Patent 7,101,866

Drug Price Trends for ARNUITY ELLIPTA
ARNUITY ELLIPTA is a drug marketed by Glaxosmithkline. There are eight patents protecting this drug.

This drug has two hundred and eighty-four patent family members in forty-one countries. There has been litigation on patents covering ARNUITY ELLIPTA

See drug price trends for ARNUITY ELLIPTA.

The generic ingredient in ARNUITY ELLIPTA is fluticasone furoate. There are twenty-nine drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the fluticasone furoate profile page.

When can SOLUPREP (chlorhexidine gluconate; isopropyl alcohol) generic drug versions launch?

Generic name: chlorhexidine gluconate; isopropyl alcohol
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 08, 2021
Generic Entry Controlled by: FDA Regulatory Exclusivity

SOLUPREP is a drug marketed by 3m Health Care. There is one patent protecting this drug.

This drug has nine patent family members in seven countries.

The generic ingredient in SOLUPREP is chlorhexidine gluconate; isopropyl alcohol. There are fifty-eight drug master file entries for this API. Four suppliers are listed for this generic product. Additional details are available on the chlorhexidine gluconate; isopropyl alcohol profile page.

When can PREPOPIK (citric acid; magnesium oxide; sodium picosulfate) generic drug versions launch?

Generic name: citric acid; magnesium oxide; sodium picosulfate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 15, 2021
Generic Entry Controlled by: FDA Regulatory Exclusivity

PREPOPIK is a drug marketed by Ferring Pharms Inc. There are two patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has thirty-one patent family members in twenty-four countries. There has been litigation on patents covering PREPOPIK

See drug price trends for PREPOPIK.

The generic ingredient in PREPOPIK is citric acid; magnesium oxide; sodium picosulfate. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the citric acid; magnesium oxide; sodium picosulfate profile page.

When can SUTENT (sunitinib malate) generic drug versions launch?

Generic name: sunitinib malate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 15, 2021
Generic Entry Controlled by: Patent 6,573,293

Drug Price Trends for SUTENT
SUTENT is a drug marketed by Cppi Cv. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has eighty patent family members in forty-two countries.

See drug price trends for SUTENT.

The generic ingredient in SUTENT is sunitinib malate. There are eight drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the sunitinib malate profile page.

When can ADASUVE (loxapine) generic drug versions launch?

Generic name: loxapine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 26, 2021
Generic Entry Controlled by: Patent 8,173,107

ADASUVE is a drug marketed by Alexza Pharms. There are eighteen patents protecting this drug.

This drug has two hundred and twenty-six patent family members in twenty countries. There has been litigation on patents covering ADASUVE

See drug price trends for ADASUVE.

The generic ingredient in ADASUVE is loxapine. There are eight drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the loxapine profile page.

When can BROVANA (arformoterol tartrate) generic drug versions launch?

Generic name: arformoterol tartrate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 09, 2021
Generic Entry Controlled by: Patent 8,110,706

Drug Price Trends for BROVANA
BROVANA is a drug marketed by Sunovion. There are eleven patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has thirty-three patent family members in thirteen countries. There has been litigation on patents covering BROVANA

See drug price trends for BROVANA.

The generic ingredient in BROVANA is arformoterol tartrate. There are four drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the arformoterol tartrate profile page.

When can EOVIST (gadoxetate disodium) generic drug versions launch?

Generic name: gadoxetate disodium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 13, 2021
Generic Entry Controlled by: Patent 6,039,931

EOVIST is a drug marketed by Bayer Hlthcare. There is one patent protecting this drug.

This drug has thirty-three patent family members in twenty-four countries.

See drug price trends for EOVIST.

The generic ingredient in EOVIST is gadoxetate disodium. One supplier is listed for this generic product. Additional details are available on the gadoxetate disodium profile page.

When can AMTURNIDE (aliskiren hemifumarate; amlodipine besylate; hydrochlorothiazide) generic drug versions launch?

Generic name: aliskiren hemifumarate; amlodipine besylate; hydrochlorothiazide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 15, 2021
Generic Entry Controlled by: Patent 8,618,174

AMTURNIDE is a drug marketed by Novartis. There are two patents protecting this drug.

This drug has one hundred and twenty-five patent family members in thirty-one countries.

The generic ingredient in AMTURNIDE is aliskiren hemifumarate; amlodipine besylate; hydrochlorothiazide. There are four drug master file entries for this API. Additional details are available on the aliskiren hemifumarate; amlodipine besylate; hydrochlorothiazide profile page.

When can NAVSTEL (calcium chloride; dextrose; magnesium chloride; oxiglutatione; potassium chloride; sodium bicarbonate; sodium chloride; sodium phosphate) generic drug versions launch?

Generic name: calcium chloride; dextrose; magnesium chloride; oxiglutatione; potassium chloride; sodium bicarbonate; sodium chloride; sodium phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 29, 2021
Generic Entry Controlled by: Patent 7,084,130

NAVSTEL is a drug marketed by Alcon Pharms Ltd. There is one patent protecting this drug.

This drug has twenty patent family members in sixteen countries.

The generic ingredient in NAVSTEL is calcium chloride; dextrose; magnesium chloride; oxiglutatione; potassium chloride; sodium bicarbonate; sodium chloride; sodium phosphate. There are two hundred and eighty-two drug master file entries for this API. Additional details are available on the calcium chloride; dextrose; magnesium chloride; oxiglutatione; potassium chloride; sodium bicarbonate; sodium chloride; sodium phosphate profile page.

When can LICART (diclofenac epolamine) generic drug versions launch?

Generic name: diclofenac epolamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 19, 2021
Generic Entry Controlled by: FDA Regulatory Exclusivity

LICART is a drug marketed by Ibsa Inst Bio.

This drug has twenty patent family members in sixteen countries.

The generic ingredient in LICART is diclofenac epolamine. There are forty-seven drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the diclofenac epolamine profile page.

When can VAZALORE (aspirin) generic drug versions launch?

Generic name: aspirin
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 19, 2021
Generic Entry Controlled by: Patent 9,351,984

VAZALORE is a drug marketed by Plx Pharma. There are five patents protecting this drug.

This drug has forty-two patent family members in eighteen countries.

The generic ingredient in VAZALORE is aspirin. There are twenty-two drug master file entries for this API. Additional details are available on the aspirin profile page.

When can FEMTRACE (estradiol acetate) generic drug versions launch?

Generic name: estradiol acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 21, 2021
Generic Entry Controlled by: Patent 6,962,908

FEMTRACE is a drug marketed by Apil. There are three patents protecting this drug.

This drug has eleven patent family members in ten countries.

The generic ingredient in FEMTRACE is estradiol acetate. There are seventy-five drug master file entries for this API. Additional details are available on the estradiol acetate profile page.

When can PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER (calcium chloride; magnesium chloride; potassium chloride; sodium bicarbonate; sodium chloride; sodium phosphate) generic drug versions launch?

Generic name: calcium chloride; magnesium chloride; potassium chloride; sodium bicarbonate; sodium chloride; sodium phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 13, 2022
Generic Entry Controlled by: FDA Regulatory Exclusivity

PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER is a drug marketed by Baxter Hlthcare Corp.

This drug has eleven patent family members in ten countries.

The generic ingredient in PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER is calcium chloride; magnesium chloride; potassium chloride; sodium bicarbonate; sodium chloride; sodium phosphate. There are two hundred and eighty-two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the calcium chloride; magnesium chloride; potassium chloride; sodium bicarbonate; sodium chloride; sodium phosphate profile page.

When can CHOLBAM (cholic acid) generic drug versions launch?

Generic name: cholic acid
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 17, 2022
Generic Entry Controlled by: FDA Regulatory Exclusivity

CHOLBAM is a drug marketed by Travere.

This drug has eleven patent family members in ten countries.

See drug price trends for CHOLBAM.

The generic ingredient in CHOLBAM is cholic acid. There are forty-four drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the cholic acid profile page.

When can VIMPAT (lacosamide) generic drug versions launch?

Generic name: lacosamide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 17, 2022
Generic Entry Controlled by: Patent RE38551

Drug Price Trends for VIMPAT
VIMPAT is a drug marketed by Ucb Inc. There is one patent protecting this drug and three Paragraph IV challenges. Seven tentatively approved generics are ready to enter the market.

This drug has twenty-two patent family members in eleven countries. There has been litigation on patents covering VIMPAT

See drug price trends for VIMPAT.

The generic ingredient in VIMPAT is lacosamide. There are twenty-two drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the lacosamide profile page.

When can JATENZO (testosterone undecanoate) generic drug versions launch?

Generic name: testosterone undecanoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 27, 2022
Generic Entry Controlled by: FDA Regulatory Exclusivity

JATENZO is a drug marketed by Clarus. There are five patents protecting this drug. Two tentatively approved generics are ready to enter the market.

This drug has twenty-four patent family members in nine countries.

See drug price trends for JATENZO.

The generic ingredient in JATENZO is testosterone undecanoate. There are sixty-nine drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the testosterone undecanoate profile page.

When can SPIRIVA (tiotropium bromide) generic drug versions launch?

Generic name: tiotropium bromide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 11, 2022
Generic Entry Controlled by: Patent RE38912

Drug Price Trends for SPIRIVA
SPIRIVA is a drug marketed by Boehringer Ingelheim. There are seventeen patents protecting this drug and one Paragraph IV challenge.

This drug has three hundred patent family members in fifty-two countries. There has been litigation on patents covering SPIRIVA

See drug price trends for SPIRIVA.

The generic ingredient in SPIRIVA is tiotropium bromide. There are eight drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the tiotropium bromide profile page.

When can ZOLADEX (goserelin acetate) generic drug versions launch?

Generic name: goserelin acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 13, 2022
Generic Entry Controlled by: Patent 4,100,274

ZOLADEX is a drug marketed by Tersera. There are three patents protecting this drug.

This drug has fifty patent family members in thirty-three countries.

See drug price trends for ZOLADEX.

The generic ingredient in ZOLADEX is goserelin acetate. There are five drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the goserelin acetate profile page.

When can COMBIGAN (brimonidine tartrate; timolol maleate) generic drug versions launch?

Generic name: brimonidine tartrate; timolol maleate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 19, 2022
Generic Entry Controlled by: Patent 7,320,976

Drug Price Trends for COMBIGAN
COMBIGAN is a drug marketed by Allergan. There are eleven patents protecting this drug and one Paragraph IV challenge. Three tentatively approved generics are ready to enter the market.

This drug has twenty-six patent family members in nineteen countries. There has been litigation on patents covering COMBIGAN

See drug price trends for COMBIGAN.

The generic ingredient in COMBIGAN is brimonidine tartrate; timolol maleate. There are eleven drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the brimonidine tartrate; timolol maleate profile page.

When can IONSYS (fentanyl hydrochloride) generic drug versions launch?

Generic name: fentanyl hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 19, 2022
Generic Entry Controlled by: Patent 6,881,208

IONSYS is a drug marketed by The Medicines Co. There are nine patents protecting this drug.

This drug has one hundred and twenty-two patent family members in thirty countries.

The generic ingredient in IONSYS is fentanyl hydrochloride. There are thirty-one drug master file entries for this API. Additional details are available on the fentanyl hydrochloride profile page.

When can DUOBRII (halobetasol propionate; tazarotene) generic drug versions launch?

Generic name: halobetasol propionate; tazarotene
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 25, 2022
Generic Entry Controlled by: FDA Regulatory Exclusivity

Drug Price Trends for DUOBRII
DUOBRII is a drug marketed by Bausch. There are five patents protecting this drug.

This drug has seventy-four patent family members in twenty-seven countries. There has been litigation on patents covering DUOBRII

See drug price trends for DUOBRII.

The generic ingredient in DUOBRII is halobetasol propionate; tazarotene. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the halobetasol propionate; tazarotene profile page.

When can ZURAGARD (isopropyl alcohol) generic drug versions launch?

Generic name: isopropyl alcohol
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 26, 2022
Generic Entry Controlled by: FDA Regulatory Exclusivity

ZURAGARD is a drug marketed by Zurex Pharma.

This drug has seventy-four patent family members in twenty-seven countries.

The generic ingredient in ZURAGARD is isopropyl alcohol. There are thirty-one drug master file entries for this API. Additional details are available on the isopropyl alcohol profile page.

When can TYMLOS (abaloparatide) generic drug versions launch?

Generic name: abaloparatide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 28, 2022
Generic Entry Controlled by: FDA Regulatory Exclusivity

Drug Price Trends for TYMLOS
TYMLOS is a drug marketed by Radius Health Inc. There are three patents protecting this drug.

This drug has thirty-nine patent family members in twenty-five countries.

See drug price trends for TYMLOS.

The generic ingredient in TYMLOS is abaloparatide. One supplier is listed for this generic product. Additional details are available on the abaloparatide profile page.

When can FRAGMIN (dalteparin sodium) generic drug versions launch?

Generic name: dalteparin sodium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 16, 2022
Generic Entry Controlled by: FDA Regulatory Exclusivity

FRAGMIN is a drug marketed by Pfizer.

This drug has thirty-nine patent family members in twenty-five countries.

See drug price trends for FRAGMIN.

The generic ingredient in FRAGMIN is dalteparin sodium. There are seven drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the dalteparin sodium profile page.

When can SLYND (drospirenone) generic drug versions launch?

Generic name: drospirenone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 23, 2022
Generic Entry Controlled by: FDA Regulatory Exclusivity

Drug Price Trends for SLYND
SLYND is a drug marketed by Exeltis Usa Inc. There are four patents protecting this drug.

This drug has forty-seven patent family members in twenty-seven countries.

See drug price trends for SLYND.

The generic ingredient in SLYND is drospirenone. There are eleven drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the drospirenone profile page.

When can ALIMTA (pemetrexed disodium) generic drug versions launch?

Generic name: pemetrexed disodium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 24, 2022
Generic Entry Controlled by: Patent 5,344,932

ALIMTA is a drug marketed by Lilly. There is one patent protecting this drug and four Paragraph IV challenges. Four tentatively approved generics are ready to enter the market.

This drug has eighteen patent family members in eleven countries. There has been litigation on patents covering ALIMTA

See drug price trends for ALIMTA.

The generic ingredient in ALIMTA is pemetrexed disodium. There are twenty-nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the pemetrexed disodium profile page.

When can YOSPRALA (aspirin; omeprazole) generic drug versions launch?

Generic name: aspirin; omeprazole
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 31, 2022
Generic Entry Controlled by: Patent 9,364,439

YOSPRALA is a drug marketed by Genus Lifesciences. There are five patents protecting this drug and one Paragraph IV challenge.

This drug has forty-six patent family members in twenty-three countries. There has been litigation on patents covering YOSPRALA

See drug price trends for YOSPRALA.

The generic ingredient in YOSPRALA is aspirin; omeprazole. There are twenty-two drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the aspirin; omeprazole profile page.

When can MYTESI (crofelemer) generic drug versions launch?

Generic name: crofelemer
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 02, 2022
Generic Entry Controlled by: Patent 7,341,744

Drug Price Trends for MYTESI
MYTESI is a drug marketed by Napo Pharms Inc. There are three patents protecting this drug.

This drug has forty-five patent family members in twenty-five countries.

See drug price trends for MYTESI.

The generic ingredient in MYTESI is crofelemer. One supplier is listed for this generic product. Additional details are available on the crofelemer profile page.

DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Colorcon
Medtronic
Express Scripts
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.